DOCSLIB.ORG

Alameda Alliance for Health

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alameda Alliance for Health Topical Antifungal Step Therapy Pharmacy Coverage Policy P&T Review Date: 07/22/2015 Policy type: ST UMC Revision Date: 06/18/2015 Program type: Standard, Value Reviewer Initials: LH Specialty: No Effective Date: 08/15/2015 Line of Business: Commercial Brand Name Generic Name GPIs Drug Class ECOZA econazole nitrate topical foam 90154035103910 Antifungal LUZU luliconazole cream 901540480037** Antifungal NAFTIN naftifine hydrochloride cream and gel 9015007800**** Antifungal MENTAX butenafine hydrochloride cream 9015002610**** Antifungal ERTACZO sertaconazole nitrate cream 9015407010**** Antifungal OXISTAT oxiconazole cream and lotion 9015406500**** Antifungal EXELDERM sulconazole cream and solution 9015407500**** Antifungal XOLEGEL ketoconazole gel 901540450040** Antifungal CRITERIA FOR COVERAGE/NONCOVERAGE UM Program Type Targeted Drugs Prerequisite Standard Trial with a least two of the XXSTTAFSN following generic or over the counter topical antifungal ECOZA, LUZU, NAFTIN, naftifine, therapies: ketoconazole, MENTAX, ERTACZO, OXISTAT, miconazole, terbinafine, econazole EXELDERM and XOLEGEL cream, clotrimazole, tolnaftate, butenafine (Lotrimin Ultra)or ciclopirox Value Trial with a least two of the XXSTTAFVN following generic or over the counter topical antifungal ECOZA, LUZU, naftifine, MENTAX, therapies: ketoconazole, ERTACZO, OXISTAT, EXELDERM and miconazole, terbinafine, econazole XOLEGEL cream, clotrimazole, tolnaftate, butenafine (Lotrimin Ultra)or ciclopirox The program applies to patients of all ages, there is a 180 day look back period for prerequisite drugs, and grandfathering does not apply. CATAMARAN, LLC. - CONFIDENTIAL AND PROPRIETARY © COPYRIGHT 2014, Catamaran, LLC. All rights reserved. Disclaimer: This document is for informational purposes only. Individual pharmacy benefit plan designs and contract language take precedence over coverage policies. Coverage may vary for Medicare or Medicaid plans. Coverage policies are reviewed and updated periodically. Page 1 of 2 Topical Antifungal Step Therapy Pharmacy Coverage Policy If prerequisites are not found within the patient’s prescription claims history, targeted drugs will be considered for coverage under the pharmacy benefit program when the following criteria are met: Patient has a diagnosis of tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ring worm), tinea versicolor or seborrheic dermatitis AND o Patient has had a trial and failure, intolerance or hypersensitivity to at least two listed generic or over the counter topical antifungal therapies: Ketoconazole Miconazole Terbinafine Econazole cream Clotrimazole Tolnaftate Butenafine (Lotrimin Ultra) Ciclopirox Reauthorization Criteria and Duration: Authorizations shall be granted for 2 months when coverage criteria are met. CATAMARAN, LLC. - CONFIDENTIAL AND PROPRIETARY © COPYRIGHT 2014, Catamaran, LLC. All rights reserved. Disclaimer: This document is for informational purposes only. Individual pharmacy benefit plan designs and contract language take precedence over coverage policies. Coverage may vary for Medicare or Medicaid plans. Coverage policies are reviewed and updated periodically. Page 2 of 2 .
Load more

Recommended publications
  • BRAND NAME COMPOSITION Packing Unit BRAND NAME
    BRAND NAME COMPOSITION Packing Unit DOIN-20 SOFT GEL CAP ISOTRETINOIN 20 MG SOFT GEL CAPS 10X1X10 BLISTER FENOGRAS 120 TAB FEXOFENADINE 120MG TABS 10X10 ALU ITRACHEM 100 CAP ITRACONAZOLE 100 MG CAPSULES 10X1X4 STRIP ITRACHEM 200 CAP ITRACONAZOLE 200 MG CAPSULES 10X1X4 STRIP KESHGAIN TABS BIOTIN10MG TABLETS(HAIR GROWTH TABS) 10X1X10 ALU SFLAZA 6 TAB DEFLAZACORT 6MG TABS 10X10 ALU TERBICHEM 250 TAB TERBINAFINE 250MG TABLETS 10X1X7 BLISTER AZYNEX 500 TAB AZITHROMYCIN 500 TAB 10X3 BLISTER BRAND NAME COMPOSITION Packing Unit BEAUTY SOAP WITH ALOE- ALOGLOW SOAP VERA,NEEM,KESAR,SANDAL,TULSI,OLIVE 75GM CARTOON OIL&GLYCERINE KETOLE SOAP KETOCONAZOLE 2% + CERTRIMIDE 0.5% 75GM CARTOON SCABICHEM SOAP PERMETHRIN 5% W/W 75GM CARTOON TRICLOSAN 0.2% + TEA TREE OIL + VIT E 0.4% + ULTRA-SHINE SOAP 75GM CARTOON TITANIUM DIOXIDE SHINE N BEAUTY SOAP NATURAL VIT.E WITH ALOE VERA SOAP 75GM CARTOON BRAND NAME COMPOSITION Packing Unit CALAMINE 15% W/V + ZINC OXIDE 5% W/V + CALACHEM LOTION 100ML CARTOON GLYCERINE 5% W/V CLEANSING LOTION (CETYL ALCOHOL 2.650% CETOCHEM LOTION 100ML CARTOON W/V + STEARYL ALCOHOL 0.260%W/V) CLOBSOL-S LOTION CLOBETASOL + SALICYLIC ACID 3% 50ML CARTOON KETOCONAZOLE 2%W/V + ZINC PYRITHIONE KETOLE-ZPTO SHAMPOO 50ML CARTOON 1%W/W SHAMPOO OCTYL METHOXY CINNAMATE 8% + SWISSGLOW-UV LOTION OXYBENZONE 6.5% + TITANIUM DIOXIDE 0.5% 100ML CARTOON SUNSCREEN LOTION SCABICHEM LOTION PERMETHRIN 5%W/V LOTION 50ML CARTOON BRAND NAME COMPOSITION Packing Unit CLINTOL POWDER CLOTRIMAZOLE 1%W/W POWDER 100GM SHRINK FINNOLE POWDER FLUCONAZOLE 0.5%W/W POWDER
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Assessment Report on Melaleuca Alternifolia (Maiden and Betch) Cheel, M
    24 November 2014 EMA/HMPC/320932/2012 Committee on Herbal Medicinal Products (HMPC) Assessment report on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Final Herbal substance(s) (binomial scientific name of Melaleuca alternifolia (Maiden and Betch) Cheel, the plant, including plant part) M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, leaf and terminal branchlets Herbal preparation(s) Melaleuca alternifolia, aetheroleum Pharmaceutical forms Herbal preparation in liquid and semi-solid dosage forms for cutaneous use or in liquid dosage form for oromucosal use. Rapporteur Marisa Delbò Assessor(s) Marisa Delbò Gioacchino Calapai Peer-reviewer Jacqueline Viguet Poupelloz 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 5 1.1. Description of the herbal substance(s),
    [Show full text]
  • Antifungals, Topical
    Antifungals, Topical Therapeutic Class Review (TCR) November 17, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. November
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • MENTAX CREAM 1% Generic Name: Butenafine Hcl Cream Sponsor : Penederm
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: Application Number : 020663 Trade Name : MENTAX CREAM 1% Generic Name: Butenafine HCl Cream Sponsor : Penederm, Inc. Approval Date: December 31, 1996 CENTER FOR DRUG EVALUATION AND RESEARCH Application Number 020663 APPROVAL LETTER DEC 3 I IW NDA 20-663 Penederm Incolpxated Attentiom John Quigley, Ph.D. Senior Vice President, Research and Development 320 Lakeside Drive, Suite A Foster City, CA W Dear Dr. QuigIey: Please refer to your December 22, 1995, new drug application submitted under section 505(b) of the Federal F@ Drug, and Cosmetic Act for Mentax (butenafine hydrochloride cream) cream, 1%. ● We acknowledge receipt of your amendments and correspondence dated December 27, 1995fi~ January 8 and 19, March 1 (two), 27 and 28, October 23,24 and 25, November 5 and 15, and December 12 and 31,1996. This new drug application provides for the treatment of tines corporis and tines cruris. We have completed the review of this application and have concluded that ;dequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed revised draft labeling.- Accordingly, the application is approved effective on the date of this letter. The final printed labeling (FPL) must be identical to the enclosed revised drall labeling. The enclosed revised draft labeling was stated to be acceptable to you in the facsimile of your letter dated December 31,1996. Marketing the product with FPL that is not identical to the enclosed revised drafl labeling may render the product misbranded and an unapproved new drug.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Clinical Policy: Topical Agents: Anti-Fungals Reference Number: OH.PHAR.PPA.90 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid
    Clinical Policy: Topical Agents: Anti-Fungals Reference Number: OH.PHAR.PPA.90 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” CICLOPIROX cream, gel, topical suspension, shampoo CICLOPIROX kit (generic of CNL® Nail lacquer kit) (generic of Loprox®) ERTACZO® (sertaconazole) CICLOPIROX solution (generic of Penlac®) EXELDERM® (sulconazole) CLOTRIMAZOLE (generic of Lotrimin®) JUBLIA® solution (efinaconazole) CLOTRIMAZOLE/BETAMETHASONE (generic of KERYDIN® solution (tavaborole) Lotrisone®) KETOCONAZOLE foam(generic of Extina®) ECONAZOLE (generic of Spectazole®) LUZU® (luliconazole) KETOCONAZOLE cream & shampoo (generic of Kuric®, MENTAX® (butenafine) Nizoral®) NAFTIFINE CREAM MICONAZOLE NAFTIN® GEL (naftifine) NYSTATIN OXICONAZOLE (generic of OXISTAT®) NYSTATIN/TRIAMCINOLONE PEDIADERM AF® cream (nystatin) TERBINAFINE (generic of Lamisil®) VUSION® ointment (miconazole/zinc) TOLNAFTATE (generic of Tinactin®) FDA approved indication(s) Ciclopirox is indicated for: • Topical treatment of mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum in immunocompetent patients (Penlac®, Ciclodan Nail Lacquer®) • Topical treatment of seborrheic dermatitis of the scalp (Loprox®) • Topical treatment of tinea corporis, tinea cruris, or tinea pedis (Epidermophyton floccosum; Microsporum canis; Trichophyton
    [Show full text]
  • Comparative Evaluation of Newer Topical Antifungal Agents in the Treatment of Superficial Fungal Infections (Tinea Or Dermatophytic) A
    A. Tamil Selvan et al. Int. Res. J. Pharm. 2013, 4 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article COMPARATIVE EVALUATION OF NEWER TOPICAL ANTIFUNGAL AGENTS IN THE TREATMENT OF SUPERFICIAL FUNGAL INFECTIONS (TINEA OR DERMATOPHYTIC) A. Tamil Selvan *, Gutha Girisha1, Vijaybhaskar2, R.Suthakaran3 * 1, 2Department of Pharmacology, Teegala Ram Reddy College of Pharmacy, Meerpet, Hyderabad, Andhra Pradesh, India 2Department of Medicine, Omni Hospital, Hyderabad, Andhra Pradesh, India *Corresponding Author Email: [email protected] Article Received on: 14/03/13 Revised on: 01/04/13 Approved for publication: 13/05/13 DOI: 10.7897/2230-8407.04651 IRJP is an official publication of Moksha Publishing House. Website: www.mokshaph.com © All rights reserved. ABSTRACT Within the past few years, new extended-spectrum triazoles and allylamines have been introduced into market. Few of them include Luliconazole, Sertaconazole and Amorolfine. It is a multicentric, randomized, open-label, comparative study to evaluate the efficacy of newer antifungal drugs. A total 150 patients needed to be enrolled in the study based on the inclusion and exclusion criteria. All the patients are aged between 18 to 80 years. Patients above the age of 18 with clinical evidence of cutaneous mycoses (commonest presentation- tinea corporis) were treated with newer antifungals like Luliconazole, Sertaconazole, Amorolfine and eberconazole and Terbinafine and a potassium hydroxide (KOH) preparation of scrapings from a selected lesion was examined microscopically and clinically evaluated. The symptoms and signs of erythema, scaling and pruritus were scored on a scale of 1 (nil) to 3 (severe). Patients were eligible for the study if they had a combined score of at least 5.
    [Show full text]